Skip to main content

Closed

SMMT: Summit Therapeutics Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-134.1%

Financially safe

Stretched

Debt / equity0.03×

Interest coverage0.0×

Current ratio6.96×

Summit Therapeutics Inc.

SMMTNASDAQ Global Market·USD·Closed

Summit Therapeutics Inc.

SMMTNASDAQ·USD·Closed

$13.02

−3.12%

$13.02

−$0.42 (3.12%)

52W Range

4thpctl

Volume

0.72×avg

Mkt Cap

10.11BUSD

P/E

-11.6TTM

Div Yield

–ann

52W Range

4thpctl

Volume

0.72×avg

Market Cap

10.11BUSD

P/E Ratio

-11.6TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings